Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimenopausal women

SABCS 2017

Published: 7 Dec 2017

Views: 1714

Rating:

Save

Prof Debu Tripathy - MD Anderson Cancer Center, Houston, USA

Prof Tripathy speaks at a SABCS 2017 press session about data from the MONALEESA-7 phase III clinical trial.

Adding the CDK4/6 inhibitor ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival for pre- and perimenopausal women with advanced hormone receptor–positive (HR-positive), HER2-negative breast cancer.

Read the news story for more.

Related Videos

Genomic testing: Awareness and effective communication between healthcare...

Prof Richard Simcock and Antonella Cardone

Genomic testing: Awareness and effective communication between healthcare professionals and patients ( Prof Richard Simcock and Antonella Cardone )

Advancing breast cancer treatment in Uganda by improving molecular testing

Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda

Advancing breast cancer treatment in Uganda by improving molecular testing ( Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda )

Somatic mutation profile of breast cancer in Uganda

Dr Manoj Menon - Fred Hutchinson Cancer Center, Seattle, USA

The current status of multiple myeloma diagnosis and treatment

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

The current status of multiple myeloma diagnosis and treatment ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Overview of the management of HER2-low breast cancer patients

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Overview of the management of HER2-low breast cancer patients ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

Spindle cell lesions of the breast

Prof Cecily Quinn - St Vincent’s University Hospital, Dublin, Ireland

Spindle cell lesions of the breast ( Prof Cecily Quinn - St Vincent’s University Hospital, Dublin, Ireland )

Breast cancer and survivorship

Dr. Ashwin Mehta - Memorial Healthcare System, Florida, USA

Breast cancer and survivorship ( Dr. Ashwin Mehta - Memorial Healthcare System, Florida, USA )

Using combined oral contraceptives may decrease risk of Ovarian, Endometrial...

Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey

Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and Colorectal cancer ( Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey )

More from ecancer